Skip to main content

Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M., Bajwah, S., Currow, D., Lovell, N., …Brown, S. (2020). Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility). Thorax, https://doi.org/10.1136/thoraxjnl-2019-213879

New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients w... Read More about Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility).

Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness (2017)
Journal Article
Johnson, M. J., Yorke, J., Hansen-Flaschen, J., Lansing, R., Ekström, M., Similowski, T., & Currow, D. (2017). Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. The European respiratory journal, 49(5), doi:10.1183/13993003.02277-2016

Copyright ©ERS 2017. Breathlessness that persists despite treatment for the underlying conditions is debilitating. Identifying this discrete entity as a clinical syndrome should raise awareness amongst patients, clinicians, service providers, researc... Read More about Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness.


;